928 related articles for article (PubMed ID: 22575238)
1. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Dinney CP; Greenberg RE; Steinberg GD
Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ.
Steinberg GD; Smith ND; Ryder K; Strangman NM; Slater SJ
Postgrad Med; 2011 May; 123(3):28-34. PubMed ID: 21566413
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
Steinberg G; Bahnson R; Brosman S; Middleton R; Wajsman Z; Wehle M
J Urol; 2000 Mar; 163(3):761-7. PubMed ID: 10687972
[TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
[TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
6. A 2-week maintenance regimen of intravesical instillation of bacillus Calmette-Guerin is safe, adherent and effective in patients with non-muscle-invasive bladder cancer: a prospective, multicenter phase II clinical trial.
Kanagawa Urological Research Group (KURG)
Jpn J Clin Oncol; 2012 Sep; 42(9):813-9. PubMed ID: 22761255
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder].
Uekado Y; Kohjimoto Y; Iba A; Kikkawa K; Shintani Y; Shinka T
Hinyokika Kiyo; 2006 Jun; 52(6):439-44. PubMed ID: 16848357
[TBL] [Abstract][Full Text] [Related]
8. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC; Steinberg GD
J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failure.
McKiernan JM; Holder DD; Ghandour RA; Barlow LJ; Ahn JJ; Kates M; Badalato GM; Roychoudhury A; Decastro GJ; Benson MC
J Urol; 2014 Dec; 192(6):1633-8. PubMed ID: 24996128
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
Barlow LJ; McKiernan JM; Benson MC
J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
[TBL] [Abstract][Full Text] [Related]
12. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
Barlow L; McKiernan J; Sawczuk I; Benson M
BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
14. Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.
McElree IM; Packiam VT; Steinberg RL; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA
J Urol; 2022 Nov; 208(5):969-977. PubMed ID: 35830552
[TBL] [Abstract][Full Text] [Related]
15. Valrubicin in refractory non-muscle invasive bladder cancer.
Sharma P; Zargar-Shoshtari K; Sexton WJ
Expert Rev Anticancer Ther; 2015; 15(12):1379-87. PubMed ID: 26569509
[TBL] [Abstract][Full Text] [Related]
16. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG.
Mugiya S; Ozono S; Nagata M; Takayama T; Ito T; Maruyama S; Hadano S; Nagae H
Jpn J Clin Oncol; 2005 Jul; 35(7):395-9. PubMed ID: 15976065
[TBL] [Abstract][Full Text] [Related]
18. [Intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG].
Mugiya S; Nagata M; Takayama T; Ozono S; Ito T; Maruyama S; Hadano S; Nagae H
Hinyokika Kiyo; 2004 Jul; 50(7):469-73. PubMed ID: 15334890
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin.
Kowalski M; Guindon J; Brazas L; Moore C; Entwistle J; Cizeau J; Jewett MA; MacDonald GC
J Urol; 2012 Nov; 188(5):1712-8. PubMed ID: 22998907
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
Lee JY; Diaz RR; Cho KS; Lim MS; Chung JS; Kim WT; Ham WS; Choi YD
J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]